Clover Corporation Limited · ASX:CLV
Clover — Shareholder Meeting (February 2016)
25 slides from Clover's shareholder meeting presentation, Feb 11, 2016
Slide 1: Chairman's Address 2012
CLOVER CORPORATION LIMITED Chairman’s Address 2012 The 2012 financial year has seen significant value added for Clover Corporation Limited (“Clover”), its staff, customers and shareholders. Clover has reported a net profit after tax for the 12 months ended 31st July 2012 of $4.4m. Based on this more
Slide 2: Chairman's Address: sales revenue and strategy
Sales revenue for 2012 was $38.4m, compared to $35.6m reported in the previous year, an increase of 7.9%. Adjusting for the extra month of trading in 2011, sales increased by 20%. Consistent with what we have outlined to shareholders before, the company’s strategy in our core business is to focus on
Slide 3: Chairman's Address: cash flow and industry consolidation
in Europe and the USA which has delayed, in some cases, the launch of new products which carry our ingredients. However the company’s innovation program and customer evaluation of new products continues, creating a platform for future growth. The usual customer approval process for new products will
Slide 4: Chairman's conclusion and outlook
In conclusion, Clover’s core business of delivering bioactive ingredients using proprietary encapsulation technology is in good shape. The outlook for 2013 is promising following the solid performance in 2012. We will continue to focus on growth markets and new value add applications in our core bus
Slide 5: Managing Director Report for AGM November 2012
Managing Director Report for AGM 30 November 2012
Slide 6: Disclaimer
DISCLAIMER The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This
Slide 7: Managing for Growth
MANAGING FOR GROWTH • Who is Clover • What Wh t h happened d in i the th pastt year • Clover’s competitive position and challenges • Clover’s strategy – Focus on the core business – Developments in medical foods • FY2013 – the year so far 3
Slide 8: Strategic Vision
STRATEGIC VISION Clover Corporation seeks to: • Identify, develop and commercialise speciality functional and nutritional ingredients in the growing “nutraceutical” & medical markets • Develop and commercialise leading edge proprietary and patented delivery technologies including the utilisation of
Slide 9: Company Description
COMPANY DESCRIPTION • Focus on two business units: – Clover Corporation focuses on innovation, obtaining the optimal return from proprietary technology and developing new business opportunities – Nu-Mega Ingredients (100% owned subsidiary) commercialises proprietary ingredient delivery and encapsula
Slide 10: Key Company Developments
KEY COMPANY DEVELOPMENTS 2012- • Building business plan for medical related 2007-2012 opportunities arising from core • Nu-Mega Ingredients 100% competencies subsidiary of Clover Corp. • Enters Phase 3 preterm • 2008 - New Innovation & infant formula trial – Sales facility in Brisbane completion exp
Slide 11: Overview of Nu-Mega Operations
OVERVIEW OF NU-MEGA OPERATIONS Maximize the use of proprietary bioactive delivery technology Algal & Tuna oil Other bioactives other oils Refine Purchase from various sources Medical & infant Emulsion formulations Tuna oil Infant formula, functional Microencapsulated foods & Powders medical applicat
Slide 12: Clover FY2012 Results
CLOVER FY2012 RESULTS year ended 31 July 2012 AUD million Year Ended Normalised* Unaudited 13 Months Ended # 31 July 2012 31 July 2012 1 Aug’10 – 31 Jul ’11 31 July 2011 Revenue ($m) $38.4 $38.4 $32.0 $35.6 Profit before tax ($m) $6.4 $7.6 $5.2 $6.1 Depreciation/Amort ($m) ($0.51) ($0.51) ($0.36) ($
Slide 13: Historical Financial Performance
HISTORICAL FINANCIAL PERFORMANCE FP2011 AUD million FY2012 FY2010 FY2009 FY2008 FY2007 (13 months) Shares on issue (m) 165.2 165.2 165.2 165.2 165.2 165.2 Total contributed equity $29.9 $28.1 $25.6 $28.3 $27.0 $23.7 ($m) Cash total ($m) $9.7 $7.4 $12.2 $9.2 $10.8 $11.0 Sales Revenue ($m) $38.4 $35.6
Slide 14: Historical Sales Revenue Performance FY2008 to FY2012
HISTORICAL SALES REVENUE PERFORMANCE FY2008 to t FY2012 CAGR since ASX listing = 13.9% p.a.# million ($) 40 30 20 10 0 FY08 FY09 FY10 FP11* FY12 Sales Revenue # Source: Pitt Capital Partners Limited * 13 month period 10
Slide 15: FY2012 Highlights – Strong Underlying Growth
FY2012 HIGHLIGHTS – STRONG UNDERLYING GROWTH • Strong growth in organic sales revenue (20.7% normalized PCP). • Focus on infant formula & children applications (97% of total sales). • Continued expansion of sales in Oceania and Asia. • Increase in proportion of sales from high value encapsulated pro
Slide 16: Continued Focus on Growth Markets & Value Added Products
CONTINUED FOCUS ON GROWTH MARKETS & VALUE ADDED PRODUCTS FY2012 Geographic • Sales revenue increased in all regions with the strongest performances during Oceania 26% th year in the i Oceania O i andd Asia. A i Asia 64% • Focus has been on infant formula & children’s food applications. Europe 6% • T
Slide 17: Delivery Systems Based on a Variety of Nutritional Bioactives
DELIVERY SYSTEMS BASED ON A VARIETY OF NUTRITIONAL BIOACTIVES • Product portfolio includes refined tuna Sales Revenue based on oil and encapsulated powders containing Diversified Bioactives in FY2012 marine oil oil, algal oils, oils other specialty oils and important micronutrients. • Encapsulation
Slide 18: Competitive Strengths – A Culture of Commercial Innovation
COMPETITIVE STRENGTHS – A CULTURE OF COMMERCIAL INNOVATION • Clover’s core strengths; – Focus on value added markets – Proprietary & patented technology – C Commercial i l focus f on innovation i ti program • Product first sales in 2010 achieved $6.5 million sales in FY12. – High quality products &
Slide 19: Research & Development Expenditure
RESEARCH & DEVELOPMENT EXPENDITURE (EXPENSED IN YEAR OF ACTIVITY) million ($) 2.00 * 1.50 1.00 0.50 0.00 FY07 FY08 FY09 FY10 FP11 FY12 R&D Expenditure * FP11 represents 13 months 15
Slide 20: Focus on the Growth of the Core Business
FOCUS ON THE GROWTH OF THE CORE BUSINESS Core business: • Continued focus on the infant formula and children’s food market. – Specialist delivery systems. – Targeted multiple bioactive delivery systems. – Improved bioactive protection. – Provision of improved value. • Currently have 6 base technolog
Slide 21: The Opportunities for Medical Applications
THE OPPORTUNITIES FOR MEDICAL APPLICATIONS Medical & Pharmaceutical applications: • Clover has supported pp strategic g clinical studies for many y years y and this assists in identifying new commercial opportunities. • Medical issues that affect preterm infants include: – Cognitive or mental impair
Slide 22: Preterm Infant Formulation
PRETERM INFANT FORMULATION • Clover developed a specialty formulation for hospital use: – Licence agreements signed & patent applications filed. – Finalised formulation and manufacturing requirements. – Successful clinical testing of the formulation and delivery system. – Product development support
Slide 23: Sales Revenue Growth of +5.9% in the First 3 Months of FY2013
SALES REVENUE GROWTH OF +5.9% 5.9% IN THE FIRST 3 MONTHS OF FY2013 million ($) Unaudited management results Sales Revenue Sales revenue from August August, September & October 19
Slide 24: FY2013 Outlook & Priorities
FY2013 OUTLOOK & PRIORITIES • Modest revenue growth in first half of FY2013. • Continued organic growth with the emphasis on Oceania & Asia including China. • Initial sales from products provided for customer evaluation in 2011. – Customer approval pp of new products p can take 2 to 4 years. y • Adv
Slide 25: Thank You
08 CLOVER CORPORATION THANK YOU Questions? NEXT GENERATION